Drug Profile
Research programme: biglycan therapeutics - Pharmahungary
Alternative Names: Biglycan™ therapy - PharmahungaryLatest Information Update: 04 Sep 2023
Price :
$50
*
At a glance
- Originator Pharmahungary Group
- Class Proteoglycans
- Mechanism of Action Proteoglycan stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Atherosclerosis; Myocardial infarction
Most Recent Events
- 04 Sep 2023 Preclinical development in Atherosclerosis andMyocardial infarction is ongoing in Hungary (Pharmahungary website, September 2023)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Atherosclerosis in Hungary
- 28 Aug 2020 No recent reports of development identified for preclinical development in Myocardial-infarction in Hungary